For media and shareholder inquiries:
Kyahn Williamson Buchan Consulting P: +61 3 9866 4722 M: +61 (0) 401 018828
If you wish to send an email please use the form below
Your Name (required)
Your Email (required)
Subject
Your Message
PAT-DX1 Conjugated to Nanoparticles Selectively Targets Tumors
PAT-DX1 Active in Pre-clinical Cancer Models
Patrys’ Deoxymab 3E10 Patent Granted in the U.S.
